Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
BioMarin Pharmaceutical Inc. - Common Stock
(NQ:
BMRN
)
57.64
+1.42 (+2.53%)
Streaming Delayed Price
Updated: 12:54 PM EDT, Apr 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
485,496
Open
57.23
Bid (Size)
57.60 (600)
Ask (Size)
57.64 (400)
Prev. Close
56.22
Today's Range
56.00 - 57.76
52wk Range
50.76 - 66.28
Shares Outstanding
183,352,255
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
2 Profitable Stocks with Promising Prospects and 1 Facing Challenges
Today 0:34 EDT
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...
Via
StockStory
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know
April 02, 2026
What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa...
Via
StockStory
Topics
Government
Stocks
World Trade
Performance
YTD
-3.0%
-3.0%
1 Month
-5.3%
-5.3%
3 Month
-4.0%
-4.0%
6 Month
+5.4%
+5.4%
1 Year
-2.6%
-2.6%
More News
Read More
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
April 02, 2026
Via
MarketMinute
Topics
Intellectual Property
Lawsuit
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Presents a Compelling Value Investment Case
↗
March 16, 2026
Via
Chartmill
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Reports Q4 2025 Revenue Beat and EPS Miss
↗
February 23, 2026
Via
Chartmill
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Presents a Compelling Value Investment Case
↗
January 24, 2026
Via
Chartmill
1 of Wall Street’s Favorite Stock with Promising Prospects and 2 We Find Risky
March 26, 2026
Via
StockStory
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026
↗
March 20, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position
↗
March 20, 2026
Via
The Motley Fool
Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks
March 19, 2026
Via
StockStory
Topics
Artificial Intelligence
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally
↗
March 16, 2026
Via
The Motley Fool
This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally
↗
March 16, 2026
Via
The Motley Fool
Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy?
↗
March 15, 2026
Via
The Motley Fool
2 Mid-Cap Stocks with Exciting Potential and 1 We Question
March 12, 2026
Via
StockStory
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing
↗
March 03, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
2 Reasons to Like BMRN (and 1 Not So Much)
March 02, 2026
Via
StockStory
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing
↗
March 02, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
↗
March 02, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
BioMarin Pharmaceutical’s (NASDAQ:BMRN) Q4 CY2025 Sales Beat Estimates
February 23, 2026
Via
StockStory
Topics
Earnings
BioMarin Pharmaceutical Earnings: What To Look For From BMRN
February 21, 2026
Via
StockStory
Topics
Artificial Intelligence
Government
World Trade
Should You Buy BioMarin Pharmaceutical Before Feb. 18?
↗
January 31, 2026
Via
The Motley Fool
Topics
Earnings
1 of Wall Street’s Favorite Stock with Exciting Potential and 2 We Find Risky
January 08, 2026
Via
StockStory
Topics
Artificial Intelligence
The Great Unlocking: 2026 Opens with a Historic Surge in Large-Cap M&A Activity
January 06, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Energy
10 Magnificent Stocks That Can Make You Richer in 2026
↗
January 05, 2026
Via
The Motley Fool
Topics
Economy
Stocks
World Trade
BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance
January 02, 2026
Via
MarketMinute
Topics
Economy
Intellectual Property
Frequently Asked Questions
Is BioMarin Pharmaceutical Inc. - Common Stock publicly traded?
Yes, BioMarin Pharmaceutical Inc. - Common Stock is publicly traded.
What exchange does BioMarin Pharmaceutical Inc. - Common Stock trade on?
BioMarin Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BioMarin Pharmaceutical Inc. - Common Stock?
The ticker symbol for BioMarin Pharmaceutical Inc. - Common Stock is BMRN on the Nasdaq Stock Market
What is the current price of BioMarin Pharmaceutical Inc. - Common Stock?
The current price of BioMarin Pharmaceutical Inc. - Common Stock is 57.64
When was BioMarin Pharmaceutical Inc. - Common Stock last traded?
The last trade of BioMarin Pharmaceutical Inc. - Common Stock was at 04/08/26 12:54 PM ET
What is the market capitalization of BioMarin Pharmaceutical Inc. - Common Stock?
The market capitalization of BioMarin Pharmaceutical Inc. - Common Stock is 10.57B
How many shares of BioMarin Pharmaceutical Inc. - Common Stock are outstanding?
BioMarin Pharmaceutical Inc. - Common Stock has 11B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.